
CLAIMS

1. A compound of Formula III1:




Formula III1

or a pharmaceutically acceptable salt thereof,

wherein

carbon 4a and carbon 10a both have *R* configuration.


2. The compound according to claim 1, wherein carbon 6 has *R* configuration thereby providing a compound of Formula IIIa1:



Formula IIIa1 ,

or a pharmaceutically acceptable salt thereof.

3. The compound according to claim 1, wherein carbon 6 has *S* configuration thereby providing a compound of Formula IIIb1:



Formula IIIb1 ,

or a pharmaceutically acceptable salt thereof.

4. A pharmaceutically acceptable salt of the compound according to any one of the preceding claims, wherein said salt is a combination of the compound of Formula III1 and an organic acid.

5. The pharmaceutically acceptable salt according to claim 4, wherein said salt is a combination of the compound of Formula IIIa1 and an organic acid.

6. The pharmaceutically acceptable salt according to claim 4 or 5, wherein said salt is a combination of the compound of Formula III1 and an organic acid in a ratio of 2:1.

7. The pharmaceutically acceptable salt according to claim 4 or 5, wherein said salt is a combination of the compound of Formula III1 and an organic acid in a ratio of 1:1.

8. The pharmaceutically acceptable salt according to any one of claims 4-7, wherein said organic acid is *D*-tartaric acid.

9. The compound according to any one of claims 1-3, or the pharmaceutically acceptable salt according to claim 8, which is in crystalline form.

10. A pharmaceutical composition comprising a therapeutically acceptable amount of a compound according to any one of claims 1-3 or 9, or
the pharmaceutically acceptable salt according to any one of claims 1-9,
in admixture with at least one pharmaceutically acceptable carrier, excipient and/or diluent.

11. The compound according to any one of claims 1-3 or 9, or
the pharmaceutically acceptable salt according to any one of claims 1-9, or
the pharmaceutical composition according to claim 10
for use as a medicament.


12. Use of a compound according to any one of claims 1-3 or 9, or
a pharmaceutically acceptable salt according to claims 1-9, or
a pharmaceutical composition according to claim 10 for the manufacture of a medicament for use in the treatment of one or more of the following: Parkinson´s disease, Huntington´s disease, Restless leg syndrome, Alzheimer´s disease, schizophrenia, attention deficit hyperactivity disorder, drug addiction.

13. The use according to claim 12, wherein the treatment comprises or consists of treatment of Parkinson´s disease.

14. The use according to claim 12 or 13, wherein the treatment is associated with no side effect(s) or mild side effect(s) comprising or consisting of nausea and/or vomiting.

15. The use according to any one of claims 12-14, wherein the treatment further comprises treatment of non-motor symptom(s) associated with Parkinson´s disease comprising or consisting of one or more of the following: cognitive functional decline, depression, anxiety, apathy, Parkinson´s disease dementia.

16. A method for preparing a compound of Formula III1 according to any one of claims 1-3 or 9, or
a pharmaceutically acceptable salt of the compound of Formula III1 according to any one of claims 1-9,
said method comprising the steps of:
a) reacting a compound of Formula II1 with a compound of Formula IV



Formula II1



Formula IV

wherein
carbon 4a and carbon 10a in the compound of Formula II1 both have *R* configuration,

X is selected from the group consisting of OH, halide and $OC(O)R^2$, and
R^2 is methyl,
optionally in the presence of an ester forming promoting agent such as a coupling reagent
thereby forming the compound of Formula III1,

b) optionally separating the compound of Formula III1, into a compound of Formula IIIa1 and a compound of Formula IIIb1 as defined in any one of claims 2-3 or 9, and

c) optionally combining the compound of Formula III1 obtained in step a) or step b) with a pharmaceutically acceptable acid thereby providing a pharmaceutically acceptable salt of the compound of Formula III1.